Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance
Cell · 2026-08 · 189 (17) · 5359-5377.e11
DOI: 10.1016/j.cell.2026.05.036 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cell, 2026-08. Verfasst von Guang Lei und 35 weiteren Autor:innen. Beteiligte Einrichtung: Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: guangle…. Hauptthemen laut MEDLINE: Cuproptosis, Immunotherapy, Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, University of Texas at Austin, University of Texas MD Anderson Cancer Center.
Abstract (Originalsprache)
Cuproptosis is a recently identified form of copper-dependent cell death that depends on ferredoxin 1 (FDX1)-mediated protein lipoylation. Here, we reveal that CD8+ T cell-mediated antitumor immunity enhances tumor cell susceptibility to cuproptosis, leading to a more potent tumor-suppressive effect of cuproptosis inducers in immunocompetent hosts compared with immunodeficient ones. Mechanistically, cuproptotic tumor cells act as a form of immunogenic cell death, releasing damage-associated molecular patterns that activate dendritic cells and enhance antitumor immunity. Reciprocally, CD8+ T cell-derived interferon (IFN)-γ enhances FDX1 transcription in tumor cells by activating the signal transducer and activator of transcription 1 (STAT1)-IFN regulatory factor-1 (IRF1) signaling axis, resulting in heightened tumor cell sensitivity to cuproptosis. Consequently, combining a cuproptosis inducer with anti-programmed cell death ligand 1 (PD-L1) therapy amplifies tumoral cuproptosis and demonstrates efficacy in overcoming PD-L1 therapy resistance across multiple preclinical models. Our findings unveil a previously unrecognized connection between antitumor immunity and cuproptosis and highlight a potential therapeutic approach to counteract tumor immunotherapy resistance by targeting this unique cell death pathway.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA. Electronic address: guanglei_csu@163.com.
- Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Molecular and Cellular Oncology, Division of Basic Sciences, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Metabolomics Core Facility, Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
- Department of Biostatistics, Division of Discovery Science, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA.
Förderung
- NCI NIH HHS
- University of Texas at Austin
- University of Texas MD Anderson Cancer Center
- Foundation for the National Institutes of Health
- Cancer Prevention and Research Institute of Texas
- National Institutes of Health
Zitieren
APA
Lei, G., Lu, Z., Xu, Z., Braun, C., Huo, D., Gao, J., Tan, L., Hong, T., Wu, S., Sun, M., Zhao, X., Li, Q., Chen, X., Yan, Y., Lee, H., Mao, C., Zhuang, L., Ku, L. T., Puebla, N., …, & Gan, B. (2026). Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell, 189(17), 5359-5377.e11. https://doi.org/10.1016/j.cell.2026.05.036
Vancouver
Lei G, Lu Z, Xu Z, Braun C, Huo D, Gao J, et al. Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance. Cell. 2026;189(17):5359-5377.e11. doi:10.1016/j.cell.2026.05.036
BibTeX
@article{Lei2026,
author = {Lei, Guang and Lu, Zhengze and Xu, Zhihao and Braun, Chen and Huo, David and Gao, Jian and Tan, Lin and Hong, Ting and Wu, Shengrong and Sun, Mingchuang and Zhao, Xi and Li, Qidong and Chen, Xiong and Yan, Yuelong and Lee, Hyemin and Mao, Chao and Zhuang, Li and Ku, Li-Ting and Puebla, Nahum and Barsoumian, Hampartsoum and Yao, Jun and Hong, Lingzhi and Zhang, Jianjun and Tran, Hai and Lee, Jiun-Kae Jack and Gibbons, Don and Vaporciyan, Ara and Heymach, John and Lin, Chunru and Gottlieb, Eyal and You, Mingjian James and Welsh, James W and Lin, Steven H and Zang, Xingxing and Li, Ziyi and Gan, Boyi},
title = {Cuproptosis-immunity crosstalk informs strategy to overcome immunotherapy resistance},
journal = {Cell},
year = {2026},
volume = {189},
number = {17},
pages = {5359--5377.e11},
doi = {10.1016/j.cell.2026.05.036}
}
EUVIMED